Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ligand Pharmaceuticals operates a royalty-based business model, owning rights to over 100 commercial programs and development-stage assets across multiple pharmaceutical partners. The company generates revenue primarily through royalties on partner drug sales (including Kyprolis, Evomela, Teriparatide), milestone payments, and licensing fees from its Captisol drug solubilization technology and OmniAb antibody discovery platform. With minimal capital requirements and 93% gross margins, Ligand functions as a pharmaceutical royalty aggregator with asymmetric upside tied to partner commercial success.
Ligand operates an asset-light model acquiring royalty rights and licensing proprietary technologies without conducting clinical trials or commercialization. Revenue scales with partner drug sales volumes with no corresponding cost increases, creating exceptional operating leverage. The company monetizes intellectual property through: (1) purchasing royalty streams on approved/late-stage drugs at discounts to NPV, (2) licensing Captisol solubilization technology for recurring material sales, and (3) providing OmniAb transgenic animal platforms for antibody discovery in exchange for milestones and royalties. Pricing power derives from Captisol's unique FDA regulatory approvals embedded in partner drug formulations and OmniAb's proprietary transgenic technology. With 24.7x current ratio and minimal capex, the model generates high cash conversion.
Kyprolis global sales performance (Amgen partnership) - largest single royalty contributor representing 20-30% of royalty revenue
New royalty acquisitions and business development deals expanding the portfolio of commercial assets
Partner clinical trial readouts and FDA approvals triggering milestone payments and future royalty streams
OmniAb platform adoption metrics - new partnerships signed and antibody candidates advancing to clinic
Captisol-enabled drug launches and penetration in specialty pharmaceutical formulations
Quarterly royalty revenue beat/miss versus Street expectations driven by partner product sales
Partner product patent expirations and biosimilar/generic competition eroding royalty streams (Kyprolis faces potential biosimilar entry post-2029)
Regulatory risk from FDA approval delays or safety issues with partnered drugs eliminating milestone payments and future royalties
Technology platform obsolescence risk if competing antibody discovery or solubilization technologies displace OmniAb and Captisol
Healthcare pricing pressure from government negotiations (IRA drug pricing provisions) reducing partner product revenues and corresponding royalty payments
Competition from larger pharmaceutical royalty companies (Royalty Pharma with $30B+ market cap) for attractive asset acquisitions, driving up purchase price multiples
Alternative antibody discovery platforms (Adimab, Harbour BioMed) competing for OmniAb partnership opportunities
Direct competition in solubilization technologies challenging Captisol's market position in specialty formulations
Concentration risk with Kyprolis representing significant portion of royalty revenue - any sales deterioration materially impacts cash flow
Valuation risk from intangible assets ($600M+ on balance sheet) requiring impairment if partner programs fail or underperform
Limited financial risk given strong liquidity (24.7x current ratio) and modest leverage (0.47 D/E), though negative operating margin requires monitoring
low - Pharmaceutical demand is non-discretionary and largely insulated from economic cycles. Royalty revenue tied to specialty oncology drugs (Kyprolis), rare disease treatments, and biosimilars exhibits minimal correlation to GDP growth. However, severe recessions could pressure healthcare budgets and delay elective procedures affecting certain partner products. Captisol sales to pharmaceutical manufacturers show modest cyclicality tied to drug development spending.
Rising rates create headwinds through two channels: (1) Higher discount rates compress NPV of long-duration royalty streams, pressuring valuation multiples for the stock (currently trading at 14.7x P/S, elevated for biotech sector), and (2) Increased financing costs for potential royalty acquisitions reduce deal economics, though Ligand's strong balance sheet (0.47 D/E) minimizes direct borrowing impact. Conversely, falling rates expand valuation multiples and make royalty acquisitions more attractive on an IRR basis.
Minimal direct exposure. Ligand's counterparty risk lies with pharmaceutical partners (Amgen, Pfizer, Takeda, others) who are investment-grade credits. The company does not extend customer credit and receives royalty payments quarterly in arrears. Tightening credit conditions could slow M&A activity in biopharma sector, reducing opportunities for new royalty acquisitions, but does not impair existing revenue streams.
growth - Investors attracted to high-margin, asset-light business model with embedded optionality from 100+ partnered programs. The 56% one-year return and 27% revenue growth appeal to growth investors seeking exposure to pharmaceutical innovation without binary clinical trial risk. However, negative net income growth (-108% YoY) and elevated P/S multiple (14.7x) indicate momentum-driven positioning rather than value characteristics. Volatility profile attracts risk-tolerant investors comfortable with quarterly earnings variability from lumpy milestone payments.
high - Stock exhibits elevated volatility driven by binary events (partner trial readouts, FDA decisions, royalty acquisition announcements) and sensitivity to biotech sector sentiment. Small revenue base ($200M TTM) means individual program outcomes create significant percentage impacts. The -7% three-month return versus +56% one-year return demonstrates momentum-driven trading patterns typical of small-cap biotech exposure.
